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Introduction: Breast carcinoma is the most common cancer in women worldwide. The incidence in-
creases with age. Elderly patients have more advanced disease than younger ones, but they have a more
favorable biologic tumor proﬁle overall. The management of breast cancer in elderly is controversial. We
report our experience with breast cancer in older than 65 years in the last 5 years, in order to assess how
many axillary dissection may have been avoided, according to disease free survival (DFS) and overall
survival (OS). Materials and methods: We enrolled in our retrospective study all over 65 year old pa-
tients referred to the Breast Unit of our Department of Clinical Medicine and Surgery at the University of
Naples Federico II from January 2009 to December 2013. The end points were: evaluation of the rate of
axillary treatment avoidable, DFS and OS. Results: We recruited 133 over 65 year old patients. Axillary
lymph node was not palpable in 109 patients. The rate of involved axillae in patients without palpable
nodes treated was 11.8%. The mean follow up was 35.7 months. At the time of data collection 3 patients
had developed IBTR. No one had axillary recurrence, independently from the chosen treatment. 2 pa-
tients died for causes different from breast cancer. Conclusion: DFS and OS are the same both in patients
with treated and no treated axilla. Even if evidences about the treatment of breast cancer in elderly are
still controversial, each patient deserves a multidisciplinary approach to discuss the best treatment
option.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Background
Breast carcinoma is the most common cancer in women
worldwide. The incidence increases with age: approximately 50% of
breast cancer occurs in women above the age of 65 and more than
30% above 70 years of age. As older women represent a fast growing
part of the population, the treatment of breast cancer in elderly
should be considered a new issue [1e6]. The management of breast
cancer in elderly is controversial. The Society of Geriatric Oncology
(SIOG) and European Society of Breast Cancer Specialists (EUSOMA)
updated the recommendations for elderly patient, but some as-
pects remains unclear. Treatment is largely based on extrapolation
of study results from younger patients or physician's personal
thought [7]. On a side breast cancer in elderly seems to have aedicine and Surgery, Breast
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65 years decreases often due to comorbidities.
Older women are more likely estrogen receptor (ER) and pro-
gesterone receptor (PgR) positive breast cancer (85% in 80e84
years old vs. 60% in 30e34); whilst HER2 oncogene tends to be
negative (10% vs 22%). Tumor size often increases because of
delayed diagnosis. Major doubts are still about node involvement
[8,9]. Even if elderly patients seem to have larger tumors and
greater lymph node involvement, compared to younger ones, they
have a more favorable biologic tumor proﬁle overall. To further
complicate the choice of the right treatment the age is correlated to
comorbidities. Aging affects normal physiological process in terms
of reductions in cardiac, respiratory and renal reserve, in addition to
cognitive impairment. These factors may limit quality of life and
adjuvant therapy rather than surgery. Comorbid diseases
commonly associated to elderly could inﬂuence life expectancy and
treatment tolerance. These variables inﬂuence treatment decisions
in clinical practice, leaving space to discussion between physician
and patient to achieve the best solution. Even if there is an
emerging consensus that older women should be managed like
younger patients, as regards surgical treatment, the functional.
Table 1
Clinical features and surgical treatment.
SLND ALND NO surgery Total
Age
65e69 28 12 9 49 (36.8%)
70e74 19 16 8 43 (32.3%)
75e79 9 6 5 20 (15.0%)
80 5 6 10 21 (15.8%)
Clinically non palpable axillary nodes 61 16 32 109 (90.0%)
Breast conserving surgery 52 22 27 101 (75.9%)
Total mastectomy 9 18 5 32 (24.0%)
Total 61 40 32 133
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undertreatment. The risk of dying from other causes often exceeds
the risk of cancer recurrence, this is why the elderly patients are
often treated less aggressively than younger patients [10].
We report our experience with breast cancer in women older
than 65 years in the last 5 years, analyzing tumor characteristics, the
treatment and the recurrence rate, above all in patients with clini-
cally negative axillary lymphnodes. The choice of the treatmentwas
based on an appropriate multidisciplinary assessment, including
geriatric, oncologic and surgical evaluation, not neglecting patients’
will. We studied the rate of axillary surgery in uninvolved axilla in
order toassesshowmanyaxillarydissectionmayhavebeenavoided,
according to disease free survival and overall survival.
2. Materials and methods
We enrolled in our retrospective study all over 65 year old pa-
tients referred to the Breast Unit of our Department of Clinical
Medicine and Surgery at the University of Naples Federico II from
January 2009 to December 2013. Data on patient tumor clinical
stage and characteristics, medical history, functional status, sur-
gery, pathology, adjuvant therapies and follow up were collected
from our Microsoft Access database. All patients underwent a
multidisciplinary evaluation with a breast team composed by sur-
geon, radiologist, pathologist and oncologist to discuss the thera-
peutic plan, after a geriatric opinion on the basis of Comprehensive
Geriatric Assessment (CGA).
The primary end point was to assess the rate of avoidable axil-
lary treatment in over 65 year old patients according to pathology
ﬁndings and recurrences, the secondary end points were disease-
free survival (DFS) and overall survival (OS).
The surgical interventions proposed were: breast conservative
surgery (BCS) or mastectomy, together with Sentinel Lymph Node
Biopsy (SLNB), Axillary Lymph Node Dissection (ALND) or no axil-
lary treatment.
BCS was proposed when tumor size was less than 3 cm and/or
when feasible according to tumor/breast ratio. Mastectomy was
indicated in tumors >5 cm or not amenable for BCS, retroareolar or
multicentric disease. SLNB was performed in all patients with
clinically negative axillary lymph node (cN0), with a good func-
tional status and life expectancy >10 years according to geriatric
assessment. ALND was performed in all patients with clinically
positive axillary lymph nodes (cNþ), in cN0 patients with contra-
indications to SLNB (allergy to methylene blue, noncompliance to
lymphoschintigraphy or personal choice) with a good functional
status and life expectancy >10 years according to geriatric assess-
ment. No axillary treatment was proposed to all cN0 patients and
was always performed according to personal patient choice, above
all in cases of poor functional status and short life expectancy.
Patient preference was always taken into consideration.
Pathology investigations included local staging, when appli-
cable; reporting histology, TNM parameters, ER, and PgR expres-
sion, ki-67 percentage, HER2 overexpression and grading.
Whole breast irradiation was performed in all patients <70 year
old, undergone to BCS. Tamoxifenwas administered to all hormone
responsive patients younger than 80 years.
Mean age, median follow up, conservative interventions rates,
total mastectomies, SLNB, ALND and no axillary treatment were
retrospectively analyzed. Pathologic results were compared to
clinical stage. Number and percentage of patients with axillary
metastatic disease in cN0were recorded for the total population and
for three groups of different axillary treatment. Postoperative follow
up examination were performed each week by the end of the ﬁrst
month after surgery, then three months after and six months after,
providing clinical examination and annual mammography to assessloco-regional and axillary recurrences. At the time of data collection
all patients were contacted by phone to verify health status.
The rate of involved and uninvolved nodes in cN0 patients were
calculated, as well as the rate of node involvement in axilla treated
patients, the rate of ipsilateral breast tumor recurrence (IBTR) and
axillary recurrence, disease free survival (DFS) and overall survival
(OS).3. Results
A total of 133 over 65 year old patients referred to our Breast
Service from January 2009 to December 2013. 3 of those were men.
Mean age was 72.4 years (range: 65e92). 49 patients age spanned
from 65 to 70 years, 63 patients from 70 to 80 years, 21 were older
than 80. None of those presented with distant metastases at the
time of surgery. BCS was performed in 101 cases, mastectomy in 32.
In 24 patients axillary examination showed clinically palpable
lymph nodes, thus ALND was performed. Axillary nodes were not
palpable in 109 patients, 61 of those underwent SLNB, 16 ALND and
32 patients were spared from axillary surgery (Table 1). Final pa-
thology report showed different histotypes: inﬁltrating ductal
carcinoma (IDC) in 104 cases, inﬁltrating lobular carcinoma (ILC) in
18, others such as medullary, papillary or mucinous carcinoma in
the remaining 11 cases. The mean diameter of the lesions was
20.5 mm. The T staging revealed: 82 cases of pT1, split as 3 pT1a, 16
pT1b and 63 pT1c; 45 were pT2, 3 pT3, and 3 pT4. Immunohisto-
chemistry showed 120 ER positive, 114 PgR positive tumors. The
average of the proliferation index ki-62 was <20% in 62 cases,20%
in 67 cases. The overexpression of proto-oncogene HER2 was pre-
sent in 39 cases.
Patients with clinically involved nodes treated with ALND
resulted in pN1 (14 cases), pN2 (7 cases), pN3 (3 cases). Among
treated cN0 patients (77) we reported 9 cases of axillary metasta-
ses, of these resulting in 3 micrometastases and 6 partial or diffuse
metastases of one single node, in most cases (3 involved nodes in
one case) (Table 4). The rate of axillary involvement with clinical
non palpable node disease treated with SLNB or ALNDwas 11.8% (9/
77). In these patients axillary dissectionwas not completed for both
surgeon and patient choice.
The rate of uninvolved axillary at ﬁnal pathology (pN0) in the
same cohort of cN0 patients with treated axilla was 88.3% (68/77).
Considering all patients (cN0 and cNþ), whose axilla was treated
(101 cases), the rate of node involvement was 32.7% (33/101)
(Table 2).
Only 37 patients underwent whole breast irradiation after sur-
gery. 100 patients received adjuvant hormone therapy. None of the
patients has been lost at follow up.
Median follow up was 35.7 months (range: 6e66 months). At
the time of data collection 3 patients developed IBTR and under-
went salvage mastectomy. No one had axillary recurrence, inde-
pendently from the opted treatment. 2 patients died from causes
other than breast cancer (Table 3).
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Axillary recurrence ratewas0%,whereas theOSwas97.7% (130/133).
4. Discussion
The treatment of breast cancer in older women still represents a
challenge for the surgeon. Several factors, different from youngerTable 2
Clinical and Pathologic ﬁndings in our population.
SLND ALND NO
surgery
Total
pN0 pN+ pN0 pN+ pNx
Surgery
Breast conserving surgery 46 6 9 12 27 101
(75.9%)
Total mastectomy 6 3 6 12 5 32
(24.0%)
Histological type
Ductal carcinoma 43 9 9 19 24 104
(78.2%)
Lobular carcinoma 5 0 6 3 4 18
(13.5)
Other inﬁltrating carcinoma
(mucinous, papillary, medullary)
4 0 1 2 4 11
(8.3%)
Multifocal/multicentric disease 3 2 2 5 2 13
(9.8%)
Stage
pT1 39 6 7 6 24 82
(61.7%)
T1a 1 e 1 e 1 3
T1b 8 2 1 e 5 16
T1c 30 4 5 6 18 63
pT2 13 3 8 16 5 45
(33.8%)
pT3 e e e 2 1 3
(2.3%)
pT4 e e 1 e 2 3
(2.3%)
Mean diameter (mm) 17.2 20.1 24.1 30.7 17.2 20.5
Node involvement
N1mic 3 e 3
N1 6 14 20
N2 e 7 7
N3 e 3 3
Total involved axillae 9 24 33
(24.8%)
Mean involved nodes 1.2 4.5
Rate of involved axilla in cN0 11.8% (9/
77)
Rate of uninvolved axilla in cN0 88.3%
(68/77)
Rate of total node involvement 32.7%
(33/101)
Distant metastases e e e e e e
Prognostic factors
Estrogen receptor positive 44 8 16 22 30 120
(90.2%)
Progesterone-receptor positive 42 8 16 22 26 114
(85.7%)
Ki-67 < 20% 26 4 14 9 13 62
(46.6%)
Ki-67  20% 26 5 2 15 19 67
(50.4%)
C-erb-B2 positive 7 2 1 4 25 39
(29.3)
C-erb-B2 negative 45 7 15 20 7 94
(70.7%)
Age
65e69 25 3 5 7 9 49
70e74 15 4 8 8 8 43
75e79 9 e 2 4 5 20
80 3 2 1 5 10 21
Mean age 70.9 72.8 69.8 73.5 75.1
Total 52 9 16 24 32 133
61 40 32patients, inﬂuence the prognosis of the breast disease and the
treatment tolerance in elderly, thus guiding therapy. Breast cancer
in elderly deserves the same attention than in youth. Age and
comorbidities must be taken into account, but how and when they
should affect the current practice is a complex issue. Older patients
with a short life expectancy, if not suitable for surgery, may
adequately be treatedwith endocrine treatment alone [11]. Patients
with hormone-negative receptors and operable breast cancer need
a careful surgical evaluation. Comorbidities often affect adjuvant
treatment, such as cytotoxic chemotherapy option, whose beneﬁt
in elderly has limited evidence [12]. Surgery related morbidity for
breast cancer is minimal and patient's diseases are rarely signiﬁcant
in determining whether she should be eligible for it. The role of
surgery is crucial in local control and accurate staging. The
adequate local control of disease is important and may have a
signiﬁcant effect on survival in women with a life expectancy of
between 10 and 15 years [13]. However, surgical treatmentmay still
be appropriate in such patients to avoid the development of dis-
tressing symptoms, such as pain, ulceration and bleeding for cancer
local progression. The accurate staging is related to tumor volume
and axillary lymph node involvement. So if the beneﬁts of the
surgical intervention are undoubted, the treatment of the axilla is
still object of debate as in younger as in older patients. Certainly
axillary clearance in cases of palpable or suspicious nodes, at ul-
trasound scan or needle aspiration citology, is mandatory.
Management and prognosis of patients presenting with clini-
cally negative axillary lymph nodes have been themain focus of our
study. The role of careful preoperative staging is crucial in order to
choose adjuvant therapies for patients above. Whilst the beneﬁt of
chemotherapy in elderly lacks as well as of the chest wall RT after
mastectomy, and remain limited to very few cases, the role of
axillary staging in clinically (and/or US, citology) uninvolved axilla
may be discussed. Fisher et al. were the ﬁrst to evidence that lymph
node involvement was an indicator, not a governor of distant
spread and that prognosis was mainly determined by tumor
biology [14]. Martelli et al. with 15 years’ follow up demonstrated
that elderly women with T1N0 ER-positive breast cancer treated
with BCS and randomized for ALND versus no axillary dissection
had no differences in OS or breast cancer mortality [15]. The In-
ternational Breast Cancer Study Group (IBCSG) trial randomized
elderly patients with cN0 ER-positive operable breast cancer for
axillary dissection versus observation, demonstrating no difference
in OS or DFS after 6.6 years of follow-up [16].
In order to choose what patients beneﬁt from primary surgery
and how to treat them, we included Comprehensive Geriatric
Assessment (CGA) in our preoperative multidisciplinary assess-
ment. The CGA is a multidimensional, interdisciplinary diagnostic
process to determine the medical, psychological and functional
capabilities of elderly patients in order to develop a coordinated
plan for their treatment [17]. Recently it has been used to assess theTable 3
Adjuvant therapy and follow-up results.
SLND ALND NO surgery Total
pN0 pN+ pN0 pN+ pNx
Whole breast irradiation 21 2 4 4 6 37 (27.8%)
Tamoxifen 41 6 15 17 21 100 (75.2%)
Ipsilateral breast tumor
recurrence
1 e e 1 1 3 (2.3%)
Axillary recurrence e e e e e 0 (0%)
Deaths for other causes e e 1 e 1 2 (1.5%)
Total 52 9 16 24 32 133
61 40
Table 4
Features of patient with metastatic sentinel node.
Patients Age Site Surgery Excised Lns Diagnosis Max diameter T N Grading ER PgR Ki67% C-erb-b2
S.S. 68 Right upper-outer quadrant BCS 1 IDC 16 1c 1 2 90 80 15 Neg
C.R. 74 Right multicentric TM 2 3 IDC þ DCIS 50 m2 1mic 3 90 80 25 Neg
T.M.L. 65 Left upper-outer quadrant BCS 5 IDC 26 2 1mic 3 Neg <3 40 Neg
V.M.P. 72 Left multifocal TM 2 2 IDC 30 m2 1mic 3 85 60 40 Pos
B.I. 73 Right upper-outer quadrant BCS 5 IDC 16 1 1 2 90 80 <10 Pos
C.P. 66 Right upper-outer quadrant TM 5 IDC 8 1 1 3 70 50 15 Neg
M.A. 70 Left lower-outer quadrant BCS 1 IDC 10 1 1 1 90 90 <10 Neg
G.I. 88 Left lower-outer quadrant BCS 1 IDC 13 1 1 2 90 50 40 Neg
D.M. 80 Right multifocal BCS 5 IDC þ DCIS 12 1 1 3 90 90 20 Neg
Mean value 72.8 3 20.1
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functional ability are effective in predicting life expectancy, but
they are time consuming and require specialist interpretation,
outside the experience of most breast surgeons, thus we let geri-
atrics to evaluate our patients [20]. In our experience we did not
consider the age per se the only factor in the decision-making
process, but we valorized the overall status and the communica-
tion with the patient. Personal choice has to be favored to assess a
proper awareness of the disease process and all available treatment
options [21,22].
BCS was feasible in most patients (75.9%) and determined a low
rate of recurrence (2.3%). The most frequent tumors were pT1c
(47.4%), ER positive (90.2%), PR positive (85.7%), HER2 negative
(70.7%); whilst ki-67 > 20% showed a slight prevalence.
27.8% of patients underwent whole breast irradiation according
to age and functional status. Tamoxifen was administered in 75.2%
of patients with good results in local control. The CALGB 9343 trial
demonstrated no beneﬁt of radiotherapy for 70 year old with T1N0
ER-positive tumors after BCS and tamoxifen, representing a good
model for population in study [23,24]. We performed ALND or SLNB
in 77 clinically negative axillae, resulting in 68 avoidable in-
terventions. If axillary surgery was avoided for these patients' we
would have lost 11.8% of metastatic axillary nodes (7.8% without
consideringmicro-metastases). Maybe the same loss occurred in no
surgery group, where axillary dissection was omitted. The prog-
nosis of all groups: pN0, pNþ or pNx seems to be superimposable,
regardless from treatment. This suggests that axillary surgery could
be safely omitted without affecting patient’ s survival, even if it
remains highly utilized by surgeons [25e27]. In addition to this
studies indicate a local progression of less than 10% (2.3% in our
experience), which, in most cases can be controlled with either
further surgery or radiotherapy without affecting overall survival
[28]. NSABP B-04 trial found that, although 40% of the patients who
underwent ALND had pathologically involved nodes, only 18% of
patients who did not undergo dissection experienced a clinically
axillary failure [23,29e34]. In our experience in elderly the rate of
involved nodes was only 11.8% and the rate of axillary recurrence
was 0%, maybe due to an older and smaller cohort, a shorter follow-
up. The low number of axillary failure was maybe due to the
endocrine therapy and the whole breast irradiation. The patients
with loco-regional recurrence were treated with salvage mastec-
tomy and are still alive. Patients with positive sentinel node were
not treated with a further axillary dissection and they haven't
experienced any axillary recurrence to date. Minimally invasive
treatment options for the breast cancer in elderly seems not
worsening prognosis, in terms of DFS and OS.5. Conclusions
The omission of axillary dissection in elderly breast cancer leads
to a lack of staging as well as prognostic information. However, itdoes not impact treatment decision. Disease free survival and
overall survival are the same both in patients with treated and no
treated axilla. Even if evidences about the treatment of breast
cancer in elderly are still controversial, each patient deserves a
multidisciplinary approach to discuss the best treatment option.
Current guidelines should be followed in over 65 with good func-
tional status and long life expectancy patients, but as recent studies
suggest a more sparing surgery should be proposed to all over 65
patients suffering from poorer performance status.Ethical approval
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